Market revenue in 2023 | USD 393.3 million |
Market revenue in 2030 | USD 988.7 million |
Growth rate | 14.1% (CAGR from 2023 to 2030) |
Largest segment | Ctc detection & enrichment methods |
Fastest growing segment | CTC Analysis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | CTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis |
Key market players worldwide | Qiagen NV, Bio-Techne Corp, Praxis Precision Medicines Inc Ordinary Shares, Aviva PLC, Biocept Inc, Neurocrine Biosciences Inc, Greiner Bio-One, Miltenyi Biotec, Icon PLC, Ecolab Inc, Arcus Biosciences Inc, Epic Corp, Screen Holdings Co Ltd, Menarini Group, Vtex Ordinary Shares - Class A, Sysmex Corp, STEMCELL Technologies |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to circulating tumor cells market will help companies and investors design strategic landscapes.
Ctc detection & enrichment methods was the largest segment with a revenue share of 66.49% in 2023. Horizon Databook has segmented the South Korea circulating tumor cells market based on ctc detection & enrichment methods, ctc direct detection methods, ctc analysis covering the revenue growth of each sub-segment from 2018 to 2030.
The market is expected to grow with a lucrative growth rate over the forecast period due to opportunities for generic manufacturers and attractive drug pricing policies for the products. An article published in June 2020 suggested that OECD countries use 70% of generics from the total medicines used.
However, South Korea accounts for 61.8% of generics by volume and 47.7% by value. This represents a significant growth opportunity for generic pharmaceuticals. The government of South Korea is focusing on reduction of the prices of generic products and expand their usage to reduce the total healthcare expenditure on pharmaceuticals.
However, the price capping on the products could negatively impact the market and opportunities for branded generic players, impeding market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea circulating tumor cells market , including forecasts for subscribers. This country databook contains high-level insights into South Korea circulating tumor cells market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account